Cargando…
Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: Subanalysis from a randomized, controlled phase 2 study
BACKGROUND AND AIMS: The FORMA‐05 study compared the efficacy and safety of human fibrinogen concentrate (HFC) versus cryoprecipitate for hemostasis in bleeding patients undergoing cytoreductive surgery for pseudomyxoma peritonei (PMP). This subanalysis explores coagulation parameters in the FORMA‐0...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521228/ https://www.ncbi.nlm.nih.gov/pubmed/37766781 http://dx.doi.org/10.1002/hsr2.1558 |
_version_ | 1785110086768656384 |
---|---|
author | Roy, Ashok Sargant, Nigel Bell, John Stanford, Sophia Solomon, Cristina Kruzhkova, Irina Knaub, Sigurd Mohamed, Faheez |
author_facet | Roy, Ashok Sargant, Nigel Bell, John Stanford, Sophia Solomon, Cristina Kruzhkova, Irina Knaub, Sigurd Mohamed, Faheez |
author_sort | Roy, Ashok |
collection | PubMed |
description | BACKGROUND AND AIMS: The FORMA‐05 study compared the efficacy and safety of human fibrinogen concentrate (HFC) versus cryoprecipitate for hemostasis in bleeding patients undergoing cytoreductive surgery for pseudomyxoma peritonei (PMP). This subanalysis explores coagulation parameters in the FORMA‐05 patients, with a focus on the seven patients who developed thromboembolic events (TEEs). METHODS: FORMA‐05 was a prospective, randomized, controlled phase 2 study in which patients with predicted blood loss ≥2 L received HFC (4 g) or cryoprecipitate (two pools of five units), repeated as needed. Plasma fibrinogen, platelet count, factor (F) XIII, FVIII, von Willebrand Factor (VWF) antigen and ristocetin cofactor activity levels, EXTEM A20, FIBTEM A20, and endogenous thrombin potential (ETP) were measured perioperatively. RESULTS: Fibrinogen, platelet count, EXTEM and FIBTEM A20, FXIII, FVIII, VWF levels, and ETP were maintained throughout surgery in both the HFC group (N = 21) and the cryoprecipitate group (N = 23). Seven TEEs were observed in the cryoprecipitate group. The two patients developing deep vein thromboses (DVT) appeared to have a procoagulant status preoperatively, with distinctively higher fibrinogen level, FIBTEM A20, and platelet levels, all of which persisted perioperatively. The five patients developing pulmonary embolism (PE) had slightly higher VWF levels preoperatively, with a disproportionate increase intraoperatively (postcryoprecipitate administration) and postoperatively. CONCLUSIONS: Patients treated with HFC versus cryoprecipitate showed broad overlaps in coagulation parameters. Patients with PE experienced a disproportionate VWF rise following cryoprecipitate administration, whereas patients developing DVT displayed a procoagulant status before and following surgery. Preoperative testing may allow these patients to be identified. |
format | Online Article Text |
id | pubmed-10521228 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105212282023-09-27 Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: Subanalysis from a randomized, controlled phase 2 study Roy, Ashok Sargant, Nigel Bell, John Stanford, Sophia Solomon, Cristina Kruzhkova, Irina Knaub, Sigurd Mohamed, Faheez Health Sci Rep Original Research BACKGROUND AND AIMS: The FORMA‐05 study compared the efficacy and safety of human fibrinogen concentrate (HFC) versus cryoprecipitate for hemostasis in bleeding patients undergoing cytoreductive surgery for pseudomyxoma peritonei (PMP). This subanalysis explores coagulation parameters in the FORMA‐05 patients, with a focus on the seven patients who developed thromboembolic events (TEEs). METHODS: FORMA‐05 was a prospective, randomized, controlled phase 2 study in which patients with predicted blood loss ≥2 L received HFC (4 g) or cryoprecipitate (two pools of five units), repeated as needed. Plasma fibrinogen, platelet count, factor (F) XIII, FVIII, von Willebrand Factor (VWF) antigen and ristocetin cofactor activity levels, EXTEM A20, FIBTEM A20, and endogenous thrombin potential (ETP) were measured perioperatively. RESULTS: Fibrinogen, platelet count, EXTEM and FIBTEM A20, FXIII, FVIII, VWF levels, and ETP were maintained throughout surgery in both the HFC group (N = 21) and the cryoprecipitate group (N = 23). Seven TEEs were observed in the cryoprecipitate group. The two patients developing deep vein thromboses (DVT) appeared to have a procoagulant status preoperatively, with distinctively higher fibrinogen level, FIBTEM A20, and platelet levels, all of which persisted perioperatively. The five patients developing pulmonary embolism (PE) had slightly higher VWF levels preoperatively, with a disproportionate increase intraoperatively (postcryoprecipitate administration) and postoperatively. CONCLUSIONS: Patients treated with HFC versus cryoprecipitate showed broad overlaps in coagulation parameters. Patients with PE experienced a disproportionate VWF rise following cryoprecipitate administration, whereas patients developing DVT displayed a procoagulant status before and following surgery. Preoperative testing may allow these patients to be identified. John Wiley and Sons Inc. 2023-09-26 /pmc/articles/PMC10521228/ /pubmed/37766781 http://dx.doi.org/10.1002/hsr2.1558 Text en © 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Roy, Ashok Sargant, Nigel Bell, John Stanford, Sophia Solomon, Cristina Kruzhkova, Irina Knaub, Sigurd Mohamed, Faheez Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: Subanalysis from a randomized, controlled phase 2 study |
title | Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: Subanalysis from a randomized, controlled phase 2 study |
title_full | Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: Subanalysis from a randomized, controlled phase 2 study |
title_fullStr | Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: Subanalysis from a randomized, controlled phase 2 study |
title_full_unstemmed | Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: Subanalysis from a randomized, controlled phase 2 study |
title_short | Comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: Subanalysis from a randomized, controlled phase 2 study |
title_sort | comparison of coagulation parameters associated with fibrinogen concentrate and cryoprecipitate for treatment of bleeding in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: subanalysis from a randomized, controlled phase 2 study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521228/ https://www.ncbi.nlm.nih.gov/pubmed/37766781 http://dx.doi.org/10.1002/hsr2.1558 |
work_keys_str_mv | AT royashok comparisonofcoagulationparametersassociatedwithfibrinogenconcentrateandcryoprecipitatefortreatmentofbleedinginpatientsundergoingcytoreductivesurgeryforpseudomyxomaperitoneisubanalysisfromarandomizedcontrolledphase2study AT sargantnigel comparisonofcoagulationparametersassociatedwithfibrinogenconcentrateandcryoprecipitatefortreatmentofbleedinginpatientsundergoingcytoreductivesurgeryforpseudomyxomaperitoneisubanalysisfromarandomizedcontrolledphase2study AT belljohn comparisonofcoagulationparametersassociatedwithfibrinogenconcentrateandcryoprecipitatefortreatmentofbleedinginpatientsundergoingcytoreductivesurgeryforpseudomyxomaperitoneisubanalysisfromarandomizedcontrolledphase2study AT stanfordsophia comparisonofcoagulationparametersassociatedwithfibrinogenconcentrateandcryoprecipitatefortreatmentofbleedinginpatientsundergoingcytoreductivesurgeryforpseudomyxomaperitoneisubanalysisfromarandomizedcontrolledphase2study AT solomoncristina comparisonofcoagulationparametersassociatedwithfibrinogenconcentrateandcryoprecipitatefortreatmentofbleedinginpatientsundergoingcytoreductivesurgeryforpseudomyxomaperitoneisubanalysisfromarandomizedcontrolledphase2study AT kruzhkovairina comparisonofcoagulationparametersassociatedwithfibrinogenconcentrateandcryoprecipitatefortreatmentofbleedinginpatientsundergoingcytoreductivesurgeryforpseudomyxomaperitoneisubanalysisfromarandomizedcontrolledphase2study AT knaubsigurd comparisonofcoagulationparametersassociatedwithfibrinogenconcentrateandcryoprecipitatefortreatmentofbleedinginpatientsundergoingcytoreductivesurgeryforpseudomyxomaperitoneisubanalysisfromarandomizedcontrolledphase2study AT mohamedfaheez comparisonofcoagulationparametersassociatedwithfibrinogenconcentrateandcryoprecipitatefortreatmentofbleedinginpatientsundergoingcytoreductivesurgeryforpseudomyxomaperitoneisubanalysisfromarandomizedcontrolledphase2study |